ResMed
(NYSE:RMD)
$198.03
1.70[0.87%]
At close: Mar 28
$198.03
0[0.00%]
After Hours: 4:20PM EDT
Consensus Rating1
Buy
Highest Price Target1
$300.00
Lowest Price Target1
$169.00
Consensus Price Target1
$162.63

ResMed Stock (NYSE:RMD), Analyst Ratings, Price Targets, Predictions

ResMed Inc has a consensus price target of $162.63, established from looking at the 62 latest analyst ratings. The last 3 analyst ratings were released from Mizuho, Keybanc, and Oppenheimer on March 27, 2024, February 6, 2024, and January 30, 2024. With an average price target of $215.67 between Mizuho, Keybanc, and Oppenheimer, there's an implied 8.91% upside for ResMed Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Oct 23
3
Jan
5
1
Feb
1
Mar
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Mizuho
Keybanc
Oppenheimer
UBS
RBC Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for ResMed

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/27/2024RMDBuy Now
ResMed
$198.038.57%Mizuho
Anthony Petrone
$215 → $215MaintainsBuyGet Alert
02/06/2024RMDBuy Now
ResMed
$198.0314.63%Keybanc
Brett Fishbin
→ $227Initiates → OverweightGet Alert
01/30/2024RMDBuy Now
ResMed
$198.033.52%Oppenheimer
Suraj Kalia
$185 → $205MaintainsOutperformGet Alert
01/30/2024RMDBuy Now
ResMed
$198.038.57%Mizuho
Anthony Petrone
$195 → $215MaintainsBuyGet Alert
01/26/2024RMDBuy Now
ResMed
$198.03-1.53%Mizuho
Anthony Petrone
$180 → $195MaintainsBuyGet Alert
01/25/2024RMDBuy Now
ResMed
$198.03-9.1%UBS
Saul Hadassin
$175 → $180MaintainsNeutralGet Alert
01/25/2024RMDBuy Now
ResMed
$198.03-8.09%RBC Capital
Craig Wong-Pan
$181 → $182MaintainsSector PerformGet Alert
01/25/2024RMDBuy Now
ResMed
$198.038.57%Needham
Mike Matson
$180 → $215MaintainsBuyGet Alert
01/09/2024RMDBuy Now
ResMed
$198.03-1.53%JP Morgan
David Low
$160 → $195MaintainsOverweightGet Alert
10/31/2023RMDBuy Now
ResMed
$198.03-19.2%Mizuho
Anthony Petrone
$180 → $160MaintainsBuyGet Alert
10/27/2023RMDBuy Now
ResMed
$198.03-14.66%Morgan Stanley
Sean Laaman
→ $169UpgradeEqual-Weight → OverweightGet Alert
10/16/2023RMDBuy Now
ResMed
$198.03-11.63%Oppenheimer
Suraj Kalia
$275 → $175MaintainsOutperformGet Alert
10/12/2023RMDBuy Now
ResMed
$198.032%RBC Capital
Craig Wong-Pan
$273 → $202DowngradeOutperform → Sector PerformGet Alert
09/29/2023RMDBuy Now
ResMed
$198.03Wolfe Research
Mike Polark
DowngradeOutperform → Peer PerformGet Alert
09/18/2023RMDBuy Now
ResMed
$198.0316.14%B of A Securities
Lyanne Harrison
$250 → $230MaintainsBuyGet Alert
09/13/2023RMDBuy Now
ResMed
$198.03-9.1%Mizuho
Anthony Petrone
$255 → $180MaintainsBuyGet Alert
09/06/2023RMDBuy Now
ResMed
$198.03-9.1%Needham
Mike Matson
→ $180UpgradeHold → BuyGet Alert
09/05/2023RMDBuy Now
ResMed
$198.03-14.15%UBS
Saul Hadassin
$265 → $170DowngradeBuy → NeutralGet Alert
08/14/2023RMDBuy Now
ResMed
$198.0337.86%RBC Capital
Craig Wong-Pan
$284 → $273MaintainsOutperformGet Alert

FAQ

Q

What is the target price for ResMed (RMD)?

A

The latest price target for ResMed (NYSE: RMD) was reported by Mizuho on March 27, 2024. The analyst firm set a price target for $215.00 expecting RMD to rise to within 12 months (a possible 8.57% upside). 26 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ResMed (RMD)?

A

The latest analyst rating for ResMed (NYSE: RMD) was provided by Mizuho, and ResMed maintained their buy rating.

Q

When was the last upgrade for ResMed (RMD)?

A

The last upgrade for ResMed Inc happened on October 27, 2023 when Morgan Stanley raised their price target to $169. Morgan Stanley previously had an equal-weight for ResMed Inc.

Q

When was the last downgrade for ResMed (RMD)?

A

The last downgrade for ResMed Inc happened on October 12, 2023 when RBC Capital changed their price target from $273 to $202 for ResMed Inc.

Q

When is the next analyst rating going to be posted or updated for ResMed (RMD)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ResMed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ResMed was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.

Q

Is the Analyst Rating ResMed (RMD) correct?

A

While ratings are subjective and will change, the latest ResMed (RMD) rating was a maintained with a price target of $215.00 to $215.00. The current price ResMed (RMD) is trading at is $198.03, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch